The First Placebo-Controlled Trial in Cryopyrin-Associated Periodic Syndromes (CAPS): IL-1 Trap (rilonacept) Markedly Reduces Clinical and Laboratory Abnormalities in Patients with Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS)

✍ Scribed by Hoffman, H.M.; Weinstein, S.P.; Amar, N.J.; Throne, M.L.; Boling, E.P.; Grimes, I.M.; Belomestnov, P.; Stein, D.R.; Vicary, C.; Mellis, S.J.

• Book ID: 119279037
• Publisher: Elsevier Science
• Year: 2007
• Tongue: English
• Weight: 43 KB
• Volume: 119
• Category: Article
• ISSN: 1097-6825
• DOI: 10.1016/j.jaci.2006.12.631